TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurotech International Ltd. ( (AU:NTI) ) has issued an update.
Neurotech International Limited announced the issuance of ordinary fully paid shares without disclosure to investors under Part 6D.2 of the Corporations Act. The company has complied with relevant provisions of the Corporations Act and confirmed there is no excluded information that investors would expect in a disclosure document, indicating transparency and adherence to regulatory standards.
More about Neurotech International Ltd.
Neurotech International Limited is a clinical-stage biopharmaceutical development company primarily focused on pediatric neurological disorders. The company offers a broad-spectrum oral cannabinoid drug therapy called NTI164 and has conducted various clinical trials in Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome, with plans for a trial in spastic cerebral palsy.
YTD Price Performance: -45.00%
Average Trading Volume: 701,686
Technical Sentiment Signal: Buy
Current Market Cap: A$34.39M
Learn more about NTI stock on TipRanks’ Stock Analysis page.